The extent of aortic lymphadenectomy in locally advanced cervical cancer impacts on survival by Llueca, Antoni et al.
1/12https://ejgo.org
ABSTRACT
Objective: The prognostic impact of surgical paraaortic staging remains unclear in patients 
with locally advanced cervical cancer (LACC). The objective of our study was to evaluate the 
results of the surgical technique of preoperative aortic lymphadenectomy in LACC related to 
tumor burden and disease spread to assess its influence on survival.
Methods: Data of 1,072 patients with cervical cancer were taken from 11 Spanish 
hospitals (Spain-Gynecologic Oncology Group [GOG] working group). Complete aortic 
lymphadenectomy surgery (CALS) was considered when the lymph nodes (LNs) were excised 
up to the left renal vein. The extent of the disease was performed evaluating the LNs by 
calculating the geometric means and quantifying the log odds between positive LNs and 
negative LNs. The Kaplan-Meier method was used to estimate the survival distribution. A Cox 
proportional hazards model was used to account for the influence of multiple variables.
Results: A total of 394 patients were included. Pathological analysis revealed positive 
aortic LNs in 119 patients (30%). LODDS cut-off value of −2 was established as a prognostic 
indicator. CALS and LODDS <−2 were associated with better disease free survival and overall 
survival than suboptimal aortic lymphadenectomy surgery and LODDS ≥−2. In a multivariate 
model analysis, CALS is revealed as an independent prognostic factor in LACC.
Conclusion: When performing preoperative surgical staging in LACC, it is not advisable to 
take simple samples from the regional nodes. Radical dissection of the aortic and pelvic 
regions offers a more reliable staging of the LNs and has a favorable influence on survival.
Keywords: Cervical Cancer; Survival Rate; Disease-Free Survival; Lymph Node Excision; 
Lymphatic Metastasis
INTRODUCTION
Cervical cancer spreads primarily to regional lymph nodes (LNs) [1]. Recently, the 
International Federation of Gynecology and Obstetrics (FIGO) of 2018 has modified the 
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staging of cervical cancer, including the LN status in the classification system that currently 
assigns patients with positive pelvic LN stage IIIC1 and women with aortic LN disease as 
stage IIIC2 [2].
Frequently, patients with cervical cancer are diagnosed in a locally advanced stage 
(FIGO IIA2-IVA and IB3). In these patients, the standard and most effective treatment is 
concomitant chemotherapy and pelvic radiotherapy. Aortic LN involvement is observed in 
17%–24% of patients with locally advanced cervical cancer (LACC) [3].
Determination of aortic LN status is essential for planning the irradiation field in cases of 
LACC to avoid unnecessary irradiation and decrease associated morbidity [4].
The previous data justify the need to identify patients who present with aortic LN metastases, 
and are therefore tributary to receive treatment with extended field external radiotherapy in 
that region. However, a discussion about the best way to assess aortic LN status in patients 
with LACC remains open. Imaging studies, especially positron emission tomography-
computed tomography (PET-CT), are less invasive but have low sensitivity for evaluation of 
aortic LN [5].
On the other hand, surgical staging is much more aggressive, although it provides more 
reliable information on the status of the aortic nodes. The prognostic and therapeutic value 
of paraaortic surgical staging remains unclear in patients with LACC, and there are some 
discrepancies in the scientific literature regarding this topic [6].
However, the risk of recurrence of other solid tumors according to the LN status suggests that 
the patient's prognosis or tumor recurrence may be influenced, not only by the nodal status 
in the paraaortic region, but also by the tumor burden in the LN, the number of positive or 
the location [7,8].
The number of regional nodes varies from one individual to another; therefore, it can lead 
to confusion. Underestimating the number of LN metastasis is a significant weakness of the 
staging system for cervical cancer. In an attempt to reduce this confusion, we have related the 
affected nodes with the volume of nodal disease through the log odds of positive LNs (LODDS).
The so-called LODDS, that is, the natural logarithm of odds between the number of positive 
and negative LNs, has also been described as a better discriminant prognostic factor than the 
simple positive LN count in some gastrointestinal cancers [9].
More recently, a LODDS major of −1.05 was defined as a dangerous independent prognostic 
indicator for disease free survival (DFS) in high-risk patients who underwent radical surgery 
followed by adjuvant treatment in cervical cancer. Among the various methods used for 
assessment of LN status, LODDS was the most powerful predictor associated with both, 
recurrence and overall survival (OS), as they are more discriminatory than the number of 
metastatic LNs to predict OS in cervical cancer with positive nodes (LOODS considers the 
tumor burden or the extent of the lymphadenectomy) [10].
Both pelvic and aortic surgical lymphadenectomies are performed to achieve better staging of 
the LN stage in cervical cancer. Furthermore, it allows reducing the extent of the therapeutic 
radiation field [11-13].
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There is no evidence about which is the most appropriate technique to perform such 
lymphadenectomy—LN sampling or radical dissection—or whether finally, it has any 
influence on survival [14-16].
In this study, we evaluated the surgical technique of preoperative aortic lymphadenectomy 
in the LCC related to tumor burden and the extent of the disease to assess its influence on 
survival. In this context, a multicentric retrospective registry was carried out in a cohort of 
patients with (LACC), uniformly treated in specialized cancer units in tertiary hospitals in 
Spain (Spain-Gynecologic Oncology Group [GOG] working group).
MATERIALS AND METHODS
Data from patients with LACC from 11 Spanish hospitals with a high volume of gynecological 
cancers (Spain-GOG working group) were analyzed.
From 2000 to 2016 all cases were analyzed retrospectively after receiving Institutional Board 
approval of the Vall d'Hebron Universitari Campus Hospital (PR AMI 159/2015). For the 
purpose of this study, the cases in which the data on the surgical technique were completely 
filled were selected. At admission, we obtained an informed consent allowing the use of 
clinical data for research purposes from every patient included in the study.
LACC was defined as patients with at least stage IB2, according to the latest 2009 FIGO 
classification. Exclusion criteria were: patients with stage IVB, patients treated by 
radiotherapy only, and patients with missing data for surgical staging.
The clinical LN stage was studied by magnetic resonance imaging (MRI) and/or PET-CT. 
Any nodular image on the MRI with a size greater than 10 mm was considered suspicious for 
infiltration. In PET-CT studies, focal areas of abnormal uptake of F-18 fluorodeoxyglucose 
(FDG) were assessed qualitatively, with non-detectable FDG uptake defined as negative, and 
assessed as positive when there was a moderate uptake with a marked increase in absorption 
in relation surrounding tissues.
The kind of treatment applied to these patients was decided by each center within a 
multidisciplinary oncology committee considering the characteristics of the patient and the tumor.
During surgical paraaortic staging, all nodes from the bifurcation of the aorta to the left renal 
vein were removed. Pelvic lymphadenectomy was only performed when enlarged nodes were 
found on preoperative imaging tests. Complete aortic lymphadenectomy surgery (CALS) 
was defined as a complete and radical paraaortic dissection up to the left renal vein, and 
suboptimal aortic lymphadenectomy surgery (SALS) when only a sampling of the paraaortic 
or pelvic ganglia was performed. Minimally invasive surgery, laparoscopic, or robotic, was 
used in all patients at the surgeon's discretion and according to the availability of resources.
All patients were subsequently treated by chemoradiotherapy and received external pelvic 
radiotherapy at the total dose of 45 Gy (25 fractions) in 5 weeks with a concomitant weekly 
basis of 40 mg/m2 of Cisplatin. They also received intracavitary brachytherapy (30 Gy) to 
complete external pelvic radiotherapy.
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Follow-up of patients was made under the discretion of each center. Generally, with 
gynecological explorations every 6 months, and with imaging test at least every 12 months. 
The surgery date was used to calculate DFS and OS.
LODDS was defined as: log [(Number of positive LN retrieved+0.5)/(Number of total LN 
retrieved−Number of positive LN retrieved+0.5)]. The LODDS, considering both the number 
of positive LN and the number of negative LN retrieved in the lymphadenectomy, relate the 
extent of the lymphadenectomy and the burden of LN involvement.
1. Statistical analysis
The Geometric mean, due to their mathematical characteristics, is more representative than 
the arithmetic means when there are very extreme values in the variables as it happens with 
the number of dissected LNs, since the influence of the most extreme values of both the 
highest and the lowest decreases [17].
For all these reasons, we considered that the geometric mean of the number of dissected 
nodes (total, aortic, and pelvic) is an excellent approximation to the advisable number of 
nodes to dissect in the lymphadenectomy of each area, in cases where optimal surgery has 
been performed.
A cumulative sum (CUSUM) control chart of expected minus observed deaths was used 
between the value of the LODDS on a continuous scale and the vital status—alive or dead—to 
determine the optimal cut-off point for the LODDS variable [18].
Inferential statistical analysis was based on the Mann-Whitney test for continuous variables 
and the χ2 test or Fisher's exact test for categorical variables. The Kaplan-Meier method was 
used to estimate the OS distribution. Comparisons of survival were made using the log-rank 
test. A Cox regression was performed, including possible confounding factors for OS and the 
type of lymphadenectomy performed. Values of p<0.05 were considered to denote significant 
differences. Statistical analysis was performed using Stata Statistical Software Release 16 
(StataCorp LLC, College Station, TX, USA).
RESULTS
From 2000 to 2016, 1,072 patients were treated for LACC in our institutions. Among them, 
634 had undergone surgical staging, but only 394 had complete surgical records and met the 
inclusion criteria. The patients' main clinicopathological characteristics can be seen in Table 1.
CUSUM chart obtained for LODDS was monotonic, indicating that the higher the LODDS, 
the more deaths in the follow-up, with the prognostic cut at −2 (best prognosis below −2). 
Thus, a cut-off value of −2 was established as a prognostic indicator (Fig. 1).
The median age of patients at diagnosis was 50 years (range, 24 to 79 years). Most FIGO 
patients were IIb (53%), and the most common histology was squamous cell carcinoma 
(82.8%) and adenocarcinoma (15.8%). There were no FIGO IVB patients.
The characteristics of the surgical LN retrieved are shown in Table 2. The total number of LN 
recovered was 7,238, and 766 (11%) were N1. The 171 (43%) of patients were N1; 119 (30%) of 
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patients have positive aortic LN; 92 (56%) of patients undergoing pelvic lymphadenectomy 
had positive pelvic LN. The median of positive LN in the aortic region was 2 (range, 0–31). 
Regarding the distribution of the aortic region, the aortic supramesenteric region, although 
a smaller number of LN was retrieved, a high number of positive LN were found (10%). In 
these series, the negative predictive value of imaging tests for aortic supramesenteric LN was 
89%, 93% for aortic inframesenteric LN, and 50% for pelvic LN. These outcomes indicate 
that a negative image of LN involvement is only reliable for the aortic supramesenteric and 
inframesenteric region, but no for the pelvic region. The low positive predictive values of the 
imaging tests for aortic supramesenteric, aortic inframesenteric, and pelvic LN, were 25%; 
16%; 56%, respectively. These values indicate that a positive image is not trustworthy for any 
region due to the high number of false positives.
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Table 1. Clinicopathological characteristics of the patients
Characteristics Total (n=394) SALS (n=11) CALS (n=383) p-value
Age 50.0±11.9 53.0±10.8 50.0±11.9 0.390
Body mass index (kg/m2) 26.0±5.1 29.0±5.7 26.0±5.1 0.100
Menopause 0.130
No 197 (50.0) 3 (27.3) 194 (50.7)
Yes 197 (50.0) 8 (72.7) 189 (49.3)
Tumor size 47.0±14.8 42.0±18.0 47.0±14.7 0.280
FIGO stage (2009) 0.570
Ib2 94 (23.9) 1 (9.1) 93 (24.3)
II 229 (58.3) 7 (63.6) 222 (58.2)
III 65 (16.5) 3 (27.3) 62 (16.2)
IV 5 (1.3) 0 5 (1.3)
Image LN (MRI-PET-CT) 0.320
Negative 165 (45.3) 3 (30.0) 162 (45.8)
Positive 199 (54.7) 7 (70.0) 192 (54.2)
Histological subtype 0.990
Squamous 323 (82.0) 9 (81.8) 314 (82.0)
Adenocarcinoma 62 (15.7) 2 (18.2) 60 (15.7)
Adenosquamous 5 (1.3) 0 5 (1.3)
Undifferentiated 2 (0.5) 0 2 (0.5)
Others 2 (0.5) 0 2 (0.5)
Tumor grade 0.950
G1 20 (5.2) 1 (9.1) 19 (5.1)
G2 111 (29.1) 3 (27.3) 108 (29.1)
G3 103 (27.0) 3 (27.3) 100 (27.0)
Unknown 148 (38.7) 4 (36.4) 144 (38.8)
SCC 10.0±21.7 11.0±22.7 10.0±21.7 0.830
CEA 13.0±61.1 6.0±10.4 13.0±61.9 0.800
CA199 84.0±265.1 48.0±14.6 85.0±268.0 0.850
Lymphadenectomy 0.730
Aortic 231 (58.6) 7 (63.6) 224 (58.5)
Aortic and pelvic 163 (41.4) 4 (36.4) 159 (41.5)
Chemoradiation treatment 0.310
Incomplete 14 (3.6) 1 (9.1) 13 (3.4)
Complete 380 (96.4) 10 (90.9) 370 (96.6)
Relapse 0.750
No 268 (68.0) 7 (63.6) 261 (68.1)
Yes 126 (32.0) 4 (36.4) 122 (31.9)
Last control status 0.024
Alive 236 (60.1) 3 (27.3) 233 (61.0)
Dead 157 (39.9) 8 (72.7) 149 (39.0)
Months of follow-up since surgery 40 (19–82) 18 (8–76) 40 (20–83) 0.069
Values are presented as mean±standard deviation, number (%) or median (interquartile range).
CA19.9, cancer antigen 19.9; CALS, complete aortic lymphadenectomy surgery; CEA, carcinoembryonic antigen; FIGO, International Federation of Gynecology 
and Obstetrics; LN, lymph node; MRI, magnetic resonance imaging; PET-CT, positron emission tomography-computed tomography; SALS, suboptimal aortic 
lymphadenectomy surgery; SCC, squamous cell carcinoma antigen.
Moreover, in 18% of LN retrieved, skip metastasis to the aortic supramesenteric region was 
found without the involvement of the aortic inframesenteric LNs. Similarly, 6.7% of positive 
aortic LNs and 3% in the supramesenteric region were found without pelvic LN in those cases 
where a pelvic lymphadenectomy was performed.
The geometric mean values of the total number of LNs retrieved are shown in Supplementary 
Table 1 as an indicator of the advisable extent of lymphadenectomy in patients that received 
complete lymphadenectomy in LACC.
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Fig. 1. CUSUM chart obtained for LODDS. 
CUSUM, cumulative sum; LODDS, log odds of positive lymph nodes.
Table 2. Characteristics of the surgical LN retrieved
Characteristics Total (n=394) SALS (n=11) CALS (n=383) p-value
LODDS total LN retrieved −2.0±1.5 −1.0±2.3 −2.0±1.5 0.002
LODDS total LN cut-off −2 0.049
<−2 283 (71.8) 5 (45.5) 278 (72.6)
≥−2 111 (28.2) 6 (54.5) 105 (27.4)
Total No. of LN retrieved 17 (1–83) 15 (3–30) 17 (1–83) 0.310
Total No. of positive LN retrieved 1 (0–1) 0 (0–1) 1 (0–1) 0.280
Total LN status (pN) 0.047
Negative 223 (56.6) 3 (27.3) 220 (57.4)
Positive 171 (43.4) 8 (72.7) 163 (42.6)
LODDS aortic LN −2.0±1.5 −1.0±2.3 −3.0±1.5 <0.001
LODDS aortic LN cut-off −2 0.030
<−2 291 (73.9) 5 (45.5) 286 (74.7)
≥−2 103 (26.1) 6 (54.5) 97 (25.3)
Total No of. aortic LN retrieved 13 (1–53) 10 (3–28) 13 (1–53) 0.110
Total No. of aortic positive LN retrieved 0 (0–31) 3 (0–8) 0 (0–31) 0.200
Aortic LN status (pN) 0.075
No 275 (69.8) 5 (45.5) 270 (70.5)
Yes 119 (30.2) 6 (54.5) 113 (29.5)
LODDS pelvic LN −2.0±1.4 −1.0±1.9 −2.0±1.4 0.510
Total No. of pelvic LN retrieved 9 (1–31) 14 (2–20) 9 (1–31) 0.410
Total No. of pelvic positive LN retrieved 1 (0–18) 2 (1–3) 1 (0–18) 0.840
Pelvic LN status (pN) 0.075
Negative 71 (43.6) 0 71 (44.7)
Positive 92 (56.4) 4 (100) 88 (55.3)
Values are presented as mean±standard deviation, number (%) or median (minimun–maximum).
CALS, complete aortic lymphadenectomy surgery; LN, lymph node; LODDS, log odds of positive lymph nodes; SALS, suboptimal aortic lymphadenectomy surgery.
There were 16 (4.2%) and 39 (10.2%) patients with intra and postoperative complications, 
respectively. The most frequent intraoperative complications were hemorrhagic accidents 
mainly at the ports of entry in the abdominal wall and occasionally accidental injuries 
of major vessels. The majority of cases of postoperative complications consisted in 
the appearance of lymphocysts in first place and ureteral lesions in second place. No 
postoperative mortality was observed.
1. Analysis of survival
Medians OS for CALS and SALS were 18 and 139 months, respectively (Fig. 2). Medians OS for 
aortic LODDS minor of −2, and equal or major of −2, were 161 and 36 months, respectively.
Mean follow-up was 57.3 months (95% CI=52.5–62.2). During follow-up 157 patients (39.8%) 
died. One hundred and twenty-six patients experience recurrence during follow-up. CALS 
and LODDS <−2 were associated with better DFS and OS than SALS and LODDS ≥−2 (Table 3).
Table 4 describes the multivariate Cox regression, where the extension of preoperative aortic 
lymphadenectomy is shown as an independent prognostic factor in LACC.
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Fig. 2. Medians OS for CALS and SALS (p log-rank=0.003). 
CALS, complete aortic lymphadenectomy surgery; OS, overall survival; SALS, suboptimal aortic 
lymphadenectomy surgery.
Table 3. OS and DFS of LODDS and type of surgery
Characteristics 12 mo 24 mo 36 mo 48 mo 60 mo
% OS complete surgery* 94 81 70 66 60
% OS no-optimal 55 45 45 36 36
% DFS complete surgery† 88 75 70 68 65
% DFS no-optimal 88 74 59 59 59
% OS LODDS <−2‡ 94 85 76 73 68
% OS LODDS ≥−2 87 68 51 44 39
% DFS LODDS <−2§ 88 80 75 72 70
% DFS LODDS ≥−2 88 59 55 53 50
DFS, disease free survival; LODDS, log odds of positive lymph nodes; OS, overall survival.
*p=0.003; †p=0.33; ‡p<0.001; §p=0.001.
DISCUSSION
Our study describes the extent of lymphadenectomy as an independent prognostic factor in 
patients with LACC. Patients with CALS have a reduction in the risk of disease progression or 
death of 63%.
As mentioned in the introduction, the debate about LN assessment is still open. Our results 
demonstrate kind of confusion in the preoperative imaging, mostly CT scan and PET-CT, 
in the initial assessment of tumor spread to the aortic region, due to the high rates of false-
positive LN retrieved. This fact coincides with other authors who reported similar results [19].
False-negative rates for PET CT in the aortic LN in patients with LACC have been reported as high 
as 13% with low sensitivity [20]. This coincides with our results, where a rate of 10% was obtained.
Contrarily, surgical aortic LN staging reveals a more realistic status of the aortic LN, as 
reveals the little concordance that generally exists between imaging tests and the most real 
LN stage obtained thanks to surgery.
One of the questions to be answered is the worth of performing a radical lymphadenectomy 
or a simply sampling, which we call suboptimal lymphadenectomy. Some authors reported 
a survival benefit in salvage and radical aortic lymphadenectomy either in recurrence or 
in surgical staging with negative imaging preoperative test [21,22]. In that line, our data 
demonstrate that a radical lymphadenectomy up to the renal vein improves both DFS and OS.
In rare cases, paraaortic LNs may be directly involved. A posterior cervical lymphatic trunk 
may drain lymph directly from the cervix into the paraaortic nodes, or rare cases of fusion 
between the cervical and uterine lymphatics may result in nodal metastases skipping to the 
L4 region via the gonadal vessels. Tumor emboli from the cervix can also reach the subaortic 
nodes directly via a posterior route [23-25].
8/12https://ejgo.org https://doi.org/10.3802/jgo.2021.32.e4
Aortic lymphadenectomy: a key point for survival?
Table 4. Cox regression for overall survival
Characteristics HR 95% CI p-value
Lymphadenectomy
Complete 0.37 0.17–0.81 0.01
No-optimal (reference) 1.00
Grouped FIGO stage
II 1.43 0.88–2.33 0.15
III 1.72 0.94–3.15 0.08
IV 2.30 0.52–10.08 0.27
I (reference) 1.00
Histology
Adenocarcinoma 1.61 1.01–2.55 0.04
Others 0.62 0.15–2.54 0.51
Squamous (reference) 1.00
Histologic grade
G2 1.52 0.53–4.40 0.44
G3 2.31 0.81–6.60 0.12
Unknown 1.65 0.57–4.79 0.35
G1 (reference) 1.00
Size long axis (mm) 1.00 0.99–1.01 0.65
Age 1.01 1.00–1.02 0.33
Body mass index (kg/m2) 1.01 0.98–1.04 0.54
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.
In our data, we found nodal jumps from the inframesenteric zone or pelvis to the 
supramesenteric zone, 18% and 6.7%, respectively. In these cases, surgical aortic staging 
would also have a beneficial effect by acting as cytoreduction surgery in these cases, although 
these rates are not line with previous literature where the possibility of skipping metastasis to 
the supramesenteric region is rare [26].
However, the minimum number of LN that should be harvested to qualify a 
lymphadenectomy as “adequate” is still a matter of debate. The harvest of the LN retrieved 
from the aortic region is not well defined in the literature range from 3 to 20 LN in the aortic 
area [27,28]. In our opinion, the geometric mean of LN retrieved is the best approximation to 
the ideal number of LN to be retrieved in a CALS when there is absence of more evidence.
In most solid tumors, LN stages are classified according to the number of pathologic 
nodes found in the different regions and are generally well correlated with the prognosis. 
In this way, many groups have tried to assess the LN involvement of cervical cancer and its 
implication in the prognosis. Some authors noted the negative impact of 2 or more LN on 
survival after adjuvant radiotherapy, noting the importance of the location of positive LN, 
and showed that metastasis in higher LN was associated with a higher incidence of distant 
metastases (50% vs. 16%) [29,30].
The efficacy of LODDS in gastric and colorectal cancer has already been reported in large-
scale studies, and Calero et al. [9] demonstrated the prognostic superiority of LODDS to 
classical LN staging. LODDS is a parameter that requires complex calculations and is less 
intuitive than the FIGO classification for cervical cancer. However, the strength of LODDS 
lies in their ability to discriminate patients with an equal LN stage by relating tumor burden 
to the number of LNs retrieved and thus distinguishes the different prognosis between 
patients with the same stage N, especially when there are no positive nodes.
Our data shows that a LODDS value major of −2 has a significantly higher risk of disease 
recurrence, specifically DFS, as well as worse OS. In the same line, Kwon et al. [10] found 
LODDS to be the strongest predictor for both recurrence and survival among the various 
methods used to assess LN status.
The indication for preoperative LN surgical staging in LACC is still controversial. The 
only prospective randomized study was conducted by Lai et al. [31] and concluded that 
there was no difference in DFS and OS between clinical and surgical staging. However, 
this study received much criticism for its design in which the compared groups were not 
homogeneous, and the study ended abruptly without reaching the primary endpoint. In the 
same line, our group (Spain-GOG working group), in a recent publication [13], has not been 
able to demonstrate an impact on survival for surgical staging compared to clinical ones. 
However, some other retrospective studies have found it [1]. On the other hand, the ongoing 
prospective study Lymphadenectomy in Locally Advanced Cervical Cancer Study (LiLACS) by 
Frumovitz et al. [32] should provide us with answers to all these questions. Meanwhile, our 
data demonstrate that in case of deciding to perform a preoperative aortic lymphadenectomy, 
it should be entirely up to renal vein since the extension of the lymphadenectomy has a 
favorable effect on the survival of patients with LACC.
This study has several limitations, such as the retrospective nature of the study or the absence 
of pre-established uniform protocol to manage these patients. Also, the small group sample 
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size in which LN sampling was performed. However, despite this, the comparison with the 
group subjected to radical dissection offers sufficient statistical power. On the other hand, 
the strengths of this study should be its multicenter nature and its ability to show a way of 
managing the LACC of tertiary hospitals in Spain over a long period.
It can be concluded that when the surgical staging of the LN status in LACC is undertaken, 
simple sampling of the regional nodes is not advisable. Radical dissection of the aortic and 
pelvic regions offers more reliable LN staging and has a favorable influence on survival. 
Overall, there is a moderate concordance between imaging tests and actual LN status.
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